Drug Profile

Luseogliflozin - Taisho Pharmaceutical

Alternative Names: Lusefi; Luseogliflozin hydrate; TS-071

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Taisho Pharmaceutical
Class Antihyperglycaemics; Glucosides; Phenyl ethers; Small molecules; Sugar alcohols; Sulfides
Mechanism of Action Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Type 2 diabetes mellitus
Discontinued Type 1 diabetes mellitus

Most Recent Events

17 Jun 2022 Launched for Type 2 diabetes mellitus in Japan (PO)
09 Feb 2022 Registered for Type 2 diabetes mellitus in Japan (PO)
06 Dec 2021 Taisho Pharmaceutical completes a phase III trial in Type-2-diabetes-mellitus (In children, In adolescent) in Japan (PO, Tablet) (JapicCTI-184022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com